Business Description
Ibnsina Pharma
ISIN : EGS512O1C012
Share Class Description:
CAI:ISPH: Ordinary SharesCompare
Compare
Traded in other countries / regions
ISPH.Egypt IPO Date
2017-11-09Description
Ibnsina Pharma is an Egypt based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, and packaging, market research, and analysis.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.19 | |||||
| Equity-to-Asset | 0.07 | |||||
| Debt-to-Equity | 2.65 | |||||
| Debt-to-EBITDA | 2.15 | |||||
| Interest Coverage | 1.22 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 2.36 | |||||
| Beneish M-Score | -1.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26.4 | |||||
| 3-Year EBITDA Growth Rate | 45 | |||||
| 3-Year EPS without NRI Growth Rate | -5.2 | |||||
| 3-Year Book Growth Rate | 5.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 85.93 | |||||
| Future 3-5Y Total Revenue Growth Rate | 30.81 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 81.44 | |||||
| 9-Day RSI | 75.32 | |||||
| 14-Day RSI | 71.2 | |||||
| 6-1 Month Momentum % | 114.52 | |||||
| 12-1 Month Momentum % | 94.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1 | |||||
| Quick Ratio | 0.73 | |||||
| Cash Ratio | 0.04 | |||||
| Days Inventory | 37.08 | |||||
| Days Sales Outstanding | 84.99 | |||||
| Days Payable | 116.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 3.5 | |||||
| Shareholder Yield % | -22.88 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 7.55 | |||||
| Operating Margin % | 3.81 | |||||
| Net Margin % | 0.92 | |||||
| FCF Margin % | 1.06 | |||||
| ROE % | 28.36 | |||||
| ROA % | 2.1 | |||||
| ROIC % | 24.79 | |||||
| ROC (Joel Greenblatt) % | 44.27 | |||||
| ROCE % | 74.99 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.49 | |||||
| Forward PE Ratio | 11.75 | |||||
| PE Ratio without NRI | 25.61 | |||||
| Price-to-Owner-Earnings | 131.13 | |||||
| PEG Ratio | 1.09 | |||||
| PS Ratio | 0.15 | |||||
| PB Ratio | 4.09 | |||||
| Price-to-Tangible-Book | 4.63 | |||||
| Price-to-Free-Cash-Flow | 14.43 | |||||
| Price-to-Operating-Cash-Flow | 10.51 | |||||
| EV-to-EBIT | 5.67 | |||||
| EV-to-EBITDA | 5.05 | |||||
| EV-to-Forward-EBITDA | 6.32 | |||||
| EV-to-Revenue | 0.24 | |||||
| EV-to-Forward-Revenue | 0.2 | |||||
| EV-to-FCF | 21.19 | |||||
| Price-to-Projected-FCF | 6.73 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.02 | |||||
| Price-to-Graham-Number | 2.3 | |||||
| Earnings Yield (Greenblatt) % | 17.65 | |||||
| FCF Yield % | 6.92 | |||||
| Forward Rate of Return (Yacktman) % | 20.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ibnsina Pharma Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil E£) | 48,544.316 | ||
| EPS (TTM) (E£) | 0.329 | ||
| Beta | 0 | ||
| Volatility % | 72.88 | ||
| 14-Day RSI | 71.2 | ||
| 14-Day ATR (E£) | 0.279543 | ||
| 20-Day SMA (E£) | 6.722 | ||
| 12-1 Month Momentum % | 94.03 | ||
| 52-Week Range (E£) | 2.14 - 7.59 | ||
| Shares Outstanding (Mil) | 1,008 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ibnsina Pharma Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ibnsina Pharma Stock Events
| Event | Date | Price(E£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ibnsina Pharma Frequently Asked Questions
What is Ibnsina Pharma(CAI:ISPH)'s stock price today?
The current price of CAI:ISPH is E£7.40. The 52 week high of CAI:ISPH is E£7.59 and 52 week low is E£2.14.
When is next earnings date of Ibnsina Pharma(CAI:ISPH)?
The next earnings date of Ibnsina Pharma(CAI:ISPH) is .
Does Ibnsina Pharma(CAI:ISPH) pay dividends? If so, how much?
Ibnsina Pharma(CAI:ISPH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers